CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
IL-3drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001269
NCT00001269Phase 1Completed
CompareCT.gov

Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer

National Cancer Institute (NCI)·interventional·Posted Dec 10, 2002·Updated Mar 4, 2008

In Brief

A Phase 1 clinical trial evaluating IL-3 for Breast Neoplasms and Neoplasm Metastasis. Completed, across 1 site.

Detailed Summary

This is a phase I study to determine the maximal tolerated dose of IL-3 given alone or sequentially with GM-CSF following FLAC chemotherapy in metastatic breast cancer patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms, Neoplasm Metastasis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 10, 2002
Enrollment StartMay 1, 1991
Study CompletionFeb 1, 2001
TodayJul 2, 2026
Posted 23.6 years ago

Interventions

IL-3drug